ASCO GU Symposium 2019

The ASCO Genitourinary Symposium took place in San Francisco this year with the kidney cancer sessions held on Saturday, February 16. This year featured combination therapies to treat metastatic RCC and two of the regimens that were reported on at the Symposium, the pembrolizumab/axitinib combination and the avelumab/axitinib combination were approved by the FDA for use in first-line metastatic RCC patients in April and May, respectively.

We have a detailed report on pembro/axitinib, view ACKC’s report summary Combination Therapy Pembrolizumab/Axitinib Outperforms Sunitinib and will soon publish another one on avelumab/axitinib as well as reports on other promising therapies for RCC including the reappearance of tivozanib, a tyrosine kinase inhibitor, in a Phase III trial in RCC.